: Recently published in The Lancet, CheckMate 9DW evaluated the efficacy and safety of dual immune checkpoint blockade nivolumab plus ipilimumab (Nivo/Ipi) compared to either sorafenib or lenvatinib in treatment-naive patients with unresectable hepatocellular carcinoma. This open-label, randomized phase 3 trial demonstrated that Nivo/Ipi provides an overall survival benefit versus lenvatinib or sorafenib.1.
Stefanini, B., Piscaglia, F. (2025). Nivolumab plus ipilimumab: A promising first-line therapy for hepatocellular carcinoma. MED, 6(8), 1-3 [10.1016/j.medj.2025.100783].
Nivolumab plus ipilimumab: A promising first-line therapy for hepatocellular carcinoma
Stefanini B.Primo
;Piscaglia F.
2025
Abstract
: Recently published in The Lancet, CheckMate 9DW evaluated the efficacy and safety of dual immune checkpoint blockade nivolumab plus ipilimumab (Nivo/Ipi) compared to either sorafenib or lenvatinib in treatment-naive patients with unresectable hepatocellular carcinoma. This open-label, randomized phase 3 trial demonstrated that Nivo/Ipi provides an overall survival benefit versus lenvatinib or sorafenib.1.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
